DuPont 2012 Annual Report Download - page 70

Download and view the complete annual report

Please find page 70 of the 2012 DuPont annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 136

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136



(Dollars in millions, except per share)

The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class:
 


  

 


Customer lists $ 1,847 $ (330) $ 1,517 $ 1,841 $ (220) $ 1,621
Patents 525 (127) 398 518 (77)441
Purchased and licensed technology 1,929 (1,016) 913 1,854 (878)976
Trademarks 57 (29) 28 57 (25) 32
Other1206 (98) 108 330 (151) 179
4,564 (1,600)2,964 4,600 (1,351) 3,249


In-process research and development 62 62 70 70
Microbial cell factories2306 306 306 306
Pioneer germplasm3975 975 975 975
Trademarks/tradenames 819 819 813 813
2,162 2,162 2,164 2,164
Total $6,726 $(1,600) $ 5,126 $6,764 $ (1,351) $ 5,413
1. Primarily consists of sales and grower networks, marketing and manufacturing alliances and noncompetition agreements.
2. Microbial cell factories, derived from natural microbes, are used to sustainably produce enzymes, peptides and chemicals using natural metabolic processes. The company recognized
the microbial cell factories as an intangible asset upon the acquisition of Danisco. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and
there are no legal, regulatory, contractual, or other factors which limit its useful life.
3. Pioneer germplasm is the pool of genetic source material and body of knowledge gained from the development and delivery stage of plant breeding. The company recognized germplasm
as an intangible asset upon the acquisition of Pioneer. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and there are no legal, regulatory,
contractual, or other factors which limit its useful life.
The aggregate pre-tax amortization expense from continuing operations for definite-lived intangible assets was $312, $253 and $155 for 2012, 2011 and
2010, respectively. The estimated aggregate pre-tax amortization expense from continuing operations for 2013, 2014, 2015, 2016 and 2017 is $302, $333,
$345, $301 and $173, respectively, which are primarily reported in cost of goods sold and other operating charges.

  
Commercial paper $ — $ 390
Other loans-various currencies 20 15
Long-term debt payable within one year 1,252 410
Capital lease obligations 32
$1,275 $ 817
The estimated fair value of the company's short-term borrowings, including interest rate financial instruments, was determined using level 2 inputs within the
fair value hierarchy, as described in Note 1 to the Consolidated Financial Statements. Based on quoted market prices for the same or similar issues, or on
current rates offered to the company for debt of the same remaining maturities, the fair value of the company's short-term borrowings was $1,300 and $830 at
December 31, 2012 and 2011, respectively.
F-22